TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21157892
DOI
10.1002/pbc.22686
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics MeSH
- Child MeSH
- Exons MeSH
- Gene Expression MeSH
- Oncogene Proteins, Fusion genetics MeSH
- In Situ Hybridization, Fluorescence MeSH
- Humans MeSH
- Adolescent MeSH
- Molecular Sequence Data MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Child, Preschool MeSH
- ETS Translocation Variant 6 Protein MeSH
- Core Binding Factor Alpha 2 Subunit genetics MeSH
- Proto-Oncogene Proteins c-ets genetics MeSH
- Repressor Proteins genetics MeSH
- Base Sequence MeSH
- Gene Expression Profiling MeSH
- Blotting, Western MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Oncogene Proteins, Fusion MeSH
- Core Binding Factor Alpha 2 Subunit MeSH
- Proto-Oncogene Proteins c-ets MeSH
- Repressor Proteins MeSH
- TEL-AML1 fusion protein MeSH Browser
BACKGROUND: The TEL/AML1 fusion gene which represents the most frequent genetic abnormality in childhood ALL, usually results from genomic breakpoints in TEL intron 5 and AML1 intron 1 or 2. At the protein level, the helix-loop-helix domain and exon 5-coded central region of TEL are typically fused to almost entire AML1 including DNA-binding domain. PROCEDURE: We identified two ALL patients with genomic breakpoints within TEL intron 4 resulting in variant TEL/AML1 fusion lacking the TEL exon 5-coded central region. This region was supposed to play an important role in TEL/AML1 function, particularly in TEL/AML1-mediated transcriptional repression of AML1 targets. We aimed at investigating the impact of the loss of this region on disease behavior and TEL/AML1 function. We compared clinical and biological characteristics, treatment response, and outcome of the variant versus classical TEL/AML1 cases, analyzed genome wide gene expression profiles and performed reporter gene assay. RESULTS: No distinct differences between variant and classical TEL/AML1 cases were observed including gene expression profiling and detailed immunophenotyping. By using reporter gene assay, we showed that the loss of the central region does not influence the TEL/AML1-mediated transcriptional repression. CONCLUSIONS: The deletion of the central region did not affect the TEL/AML1-specific phenotype; we did not find any relevant differences in clinical and biological features when variant versus classical TEL/AML1-positive cases were compared. Thus, our data does not support hypothesis that the central region of TEL is indispensable for TEL/AML1 driven leukemogenesis.
References provided by Crossref.org